# Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

> **NCT01471106** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01471106
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-21
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-05-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471106, "Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01471106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*